MDM2 and neoplasm: Increased numbers of CD103+ DC cells, Tbet+ EOMES− T cells, and ratios of CD8+ T cells/Treg were observed with a MDM2 inhibitor NVP-HDM201 treatment in murine tumors as well as tumor draining lymph nodes, leading to synergistic effect of NVP-HDM201 in combination with anti-PD-1 or PD-L1 antibody in syngeneic tumor models [42].